Get the Stockscreener App
1.53
2.68%
0.04
After Hours:
1.53
NanoViricides Inc stock is traded at $1.53, with a volume of 722.21K.
It is up +2.68% in the last 24 hours and up +14.18% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.49
Open:
$1.53
24h Volume:
722.21K
Relative Volume:
3.74
Market Cap:
$21.95M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-2.5932
EPS:
-0.59
Net Cash Flow:
$-6.47M
1W Performance:
+3.38%
1M Performance:
+14.18%
6M Performance:
-15.93%
1Y Performance:
+41.67%
1-Day Range:
$1.50
$1.5509
1-Week Range:
$1.4201
$1.5509
52-Week Range:
$1.0001
$3.59
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.53 | 21.95M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors USA
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News
NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz
NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA
NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News
NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news
NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA
Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
NNVC - Insider Financial
Chronic Fatigue Syndrome Market Demand and Opportunities - openPR
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick
Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey
7 Best Nanotech Penny Stocks to Buy - Insider Monkey
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit - MSN
Genital Herpes Research and Development Pipeline Market By Application, Size, Share, And Forecast (2024-2034) - Daily News Mirror
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow - Oil City Derrick
Apparent Israeli airstrike on mosque in central Gaza kills at least 18 people - Source ONE News
NanoViricides (NYSE:NNVC) Trading 4.3% Higher – Time to Buy? - Defense World
Marburgvirus Infection Industry value, Share, Technology to (2024-2036) - Daily News Mirror
Marburgvirus Infection Industry Size, Share, Technology to (2024-2034) - La Funcion mx
Oasis adds US, Canada and Mexico stops to 2025 tour - Oil City Derrick
NanoViricides prepares for Phase II trials for antiviral NV-387 - Proactive Investors USA
No arrests in South Africa mass shootings as death toll rises to 18 - Oil City Derrick
Over 90,000 Georgia residents sheltering a day after chemical plant fire sends chlorine into the air - Oil City Derrick
Rwanda reports 8 deaths linked to Ebola-like Marburg virus days after it declared an outbreak - Oil City Derrick
AT&T exits showbiz, sells remaining stake in DirecTV to private equity firm TPG for $7.6 billion - Oil City Derrick
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID - Source ONE News
China factory surveys show economy weakening, as Beijing steps up support - Oil City Derrick
Vance criticized an infrastructure law as a candidate then embraced it as a senator - Oil City Derrick
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2024 - Marketscreener.com
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM) - Oil City Derrick
Orbán aide faces backlash for saying Hungary wouldn’t have fought a Russian invasion - Oil City Derrick
The number of Americans filing for jobless aid falls to lowest level in four months - Oil City Derrick
NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement - Proactive Investors UK
Brimma Tech Unveils Advanced AUS Sandbox Solution for Enhanced Mortgage Underwriting - Oil City Derrick
Harrods apologizes to women who say they were abused by former owner Mohamed Al Fayed - Oil City Derrick
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):